1159600-41-5

Basic information

• Product Name: Basmisanil
• Synonyms: Basmisanil;(1,1-Dioxo-4-thiomorpholinyl)[6-[[3-(4-fluorophenyl)-5-methylisoxazol-4-yl]methoxy]pyridin-3-yl]methanone;RG 1662;RG-1662;RO5186582;Ladarixin;(1,1-dioxo-1λ6-thiomorpholin-4-yl)-{6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-pyridin-3-yl}-methanone
• CAS NO: 1159600-41-5
• Molecular Formula: C₂₁H₂₀FN₃O₅S
• Molecular Weight: 445.4640032
• EINECS: -0
• Mol File: 1159600-41-5.mol

Chemical Properties

• Boiling Point: 726.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.388±0.06 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 2.07±0.22(Predicted)
• CAS DataBase Reference: Basmisanil(CAS DataBase Reference)
• NIST Chemistry Reference: Basmisanil(1159600-41-5)
• EPA Substance Registry System: Basmisanil(1159600-41-5)

Safety Data

• Hazardous Substances Data: 1159600-41-5(Hazardous Substances Data)

Usage

Uses

Basmisanil is a highly selective GABAAα5 negative allosteric modulator.

Upstream product

• 33252-28-7 6-chloronicotinonitrile 
• 42202-95-9 4-fluoro-N-hydroxybenzimidoyl chloride 
• 1736-21-6 3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 954230-39-8 3-(4-fluoro-phenyl)-5-methyl-isoxazole-4-carboxylic acid ethyl ester 
• 459-23-4 4-fluorobenzaldoxime 
• 459-57-4 4-fluorobenzaldehyde 
• 1018297-63-6 [3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-yl]-methanol 
• 1159600-32-4 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid 
• 59801-62-6 1,1-dioxothiomorpholine hydrochloride 
• 39093-93-1 thiomorpholine 1,1-dioxide 
• 1159600-30-2 6-[3-(4-fluoro-phenyl)-5-methyl-isoxazol-4-ylmethoxy]-nicotinic acid methyl ester 

Relevant articles and documents

NOVEL GAMMA AMINOBUTYRIC ACID TYPE A RECEPTOR MODULATORS FOR MOOD DISORDERS

The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acti

(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV

The invention relates to an administration unit comprising a compound of formula and/or pharmaceutically acceptable salts thereof, and to a packaging comprising the administration unit according to the invention.

SOLID FORMS OF 1,L-DIOXO-4-THIOMORPHOLINYL)-[6-[[3(4-FLUOROPHENYL)-5-METHYL-4-ISOXAZOLYL]METHOXY]-3-PYRIDINYL]-METHANONE

The instant invention relates to novel solid forms of the compound of formula (I), as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these solid forms, and their

NOVEL SOLID FORMS

The instant invention relates to novel solid forms of the compound of formula (I) as well as solvates, inclusion complexes with other suitable compounds, processes for their manufacture, pharmaceutical compositions containing these solid forms, and their

PROCESS FOR THE PREPARATION OF ISOXAZOLYL- METHOXY NICOTINIC ACIDS

The present invention relates to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined herein, which is useful as an intermediate in the preparation of active pharmaceutical compounds.

PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS

The present invention relates to a process for the preparation of a compound of formula (I) which is useful as an intermediate in the preparation of active pharmaceutical compounds from a compound of formula (IV) wherein R1 and R2 ar

ISOXAZOLE-PYRIDINE DERIVATIVES

The present invention is concerned with isoxazole-pyridine derivatives of formula I wherein X, R1 to R6 are as described herein. The compounds are active on the GABA A α5 receptor binding site and useful for the treatment of cognitive disorders, such as Alzheimer's disease.